CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Common Stock Repurchased

Cash spent buying back the company's own shares.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased outflow grows to $0

Q1 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Common stock repurchased amounts to 0.0% of revenue for CAMP, versus a peer median of 0.0%.
CAMP Competitors
Common Stock Repurchased for CAMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$125K CAD——0.7%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$0 USD——0.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$0 USD———
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$0 USD———
VXRTVaxart, Inc.LTM Mar 2026$0 USD——0.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
ATYRaTyr Pharma, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CAMP) ———0.0%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.99M)(44.19M)(49.29M)(51.79M)(80.4M)
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
Deferred Income Tax00000
Stock-Based Compensation11.32M1.38M2.91M4.03M4M
Change in Working Capital1.59M373K(154K)(1.88M)13.01M
Accounts Receivables1.44M0000
Inventory5.16M0000
Accounts Payables0000(1.03M)
Other Working Capital(5.01M)373K(154K)(1.88M)14.04M
Other Non-Cash Items(11.94M)3.02M705K2.39M32.21M
Operating Cash Flow(4.22M)(38.54M)(44.16M)(45.56M)(29.55M)
Capital Expenditures(13.3M)(4.03M)(678K)(441K)(279K)
Acquisitions (Net)000036K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities5.72M0000
Investing Cash Flow(7.58M)(4.03M)(678K)(441K)(243K)
Debt Repayment—(93K)116K(824K)(208K)
Common Stock Issued000061.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.64M)100.25M185K72.49M14.93M
Financing Cash Flow(2.64M)100.16M301K71.66M75.89M
Effect of Forex Changes(965K)25.6M000
Net Change in Cash(15.4M)83.19M(44.53M)25.66M46.09M
Free Cash Flow(17.52M)(42.57M)(44.83M)(46M)(29.83M)

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.